Biosyent Inc.
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form produc… Read more
Biosyent Inc. (BIOYF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.069x
Based on the latest financial reports, Biosyent Inc. (BIOYF) has a cash flow conversion efficiency ratio of 0.069x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($2.77 Million) by net assets ($39.90 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Biosyent Inc. - Cash Flow Conversion Efficiency Trend (1997–2024)
This chart illustrates how Biosyent Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Biosyent Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biosyent Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
FLITTO Inc
KQ:300080
|
0.343x |
|
San Lien Technology
TWO:5493
|
0.050x |
|
Micro Systemation AB (publ)
ST:MSAB-B
|
0.606x |
|
AADI BIOSCIENCES DL-0001
F:3350
|
N/A |
|
Canyon Resources Ltd
AU:CAY
|
-0.257x |
|
Micro Systemation AB Series B
LSE:0FBM
|
0.011x |
|
Windlas Biotech Limited
NSE:WINDLAS
|
0.013x |
|
Gas Plus S.p.A.
LSE:0EMK
|
N/A |
Annual Cash Flow Conversion Efficiency for Biosyent Inc. (1997–2024)
The table below shows the annual cash flow conversion efficiency of Biosyent Inc. from 1997 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $35.00 Million | $8.66 Million | 0.248x | +70.19% |
| 2023-12-31 | $34.76 Million | $5.05 Million | 0.145x | -1.96% |
| 2022-12-31 | $33.36 Million | $4.95 Million | 0.148x | +0.12% |
| 2021-12-31 | $31.55 Million | $4.67 Million | 0.148x | -42.42% |
| 2020-12-31 | $26.80 Million | $6.89 Million | 0.257x | +39.11% |
| 2019-12-31 | $25.79 Million | $4.77 Million | 0.185x | -18.78% |
| 2018-12-31 | $27.61 Million | $6.29 Million | 0.228x | -22.73% |
| 2017-12-31 | $22.21 Million | $6.55 Million | 0.295x | +12.06% |
| 2016-12-31 | $16.73 Million | $4.40 Million | 0.263x | +13.69% |
| 2015-12-31 | $12.15 Million | $2.81 Million | 0.231x | -48.14% |
| 2014-12-31 | $8.16 Million | $3.64 Million | 0.446x | +2.20% |
| 2013-12-31 | $4.85 Million | $2.12 Million | 0.436x | -0.79% |
| 2012-12-31 | $2.84 Million | $1.25 Million | 0.440x | -14.20% |
| 2011-12-31 | $1.16 Million | $596.08K | 0.513x | +807.97% |
| 2010-12-31 | $671.02K | $37.89K | 0.056x | +110.00% |
| 2009-12-31 | $607.02K | $-342.79K | -0.565x | -85.44% |
| 2008-12-31 | $854.08K | $-260.09K | -0.305x | -2495.85% |
| 2007-12-31 | $1.12 Million | $14.25K | 0.013x | -92.99% |
| 2006-12-31 | $1.23 Million | $222.26K | 0.181x | -80.32% |
| 2005-12-31 | $811.46K | $747.81K | 0.922x | +370.31% |
| 2004-12-31 | $306.20K | $-104.39K | -0.341x | +66.97% |
| 2003-12-31 | $606.86K | $-626.35K | -1.032x | -170.90% |
| 2002-12-31 | $621.73K | $905.12K | 1.456x | +527.53% |
| 2001-12-31 | $990.86K | $-337.40K | -0.341x | +43.18% |
| 2000-12-31 | $210.36K | $-126.07K | -0.599x | -79.79% |
| 1999-12-31 | $600.00K | $-200.00K | -0.333x | +63.33% |
| 1998-12-31 | $1.10 Million | $-1.00 Million | -0.909x | -13.64% |
| 1997-12-31 | $500.00K | $-400.00K | -0.800x | -- |